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Exclusive Enteral Nutrition and Corticosteroids: Two Effective Methods of Induction 
Treatment in Crohn’s Disease  
Sarah Hutchison & Rachel Stottlar 
Abstract 
Objective: To compare the effectiveness of corticosteroids (CS) versus exclusive enteral nutrition (EEN), 
as induction therapy of Crohn’s disease to induce remission. Design: Systematic literature review. 
Methods: Searches were done in PubMed utilizing the terms: enteral nutrition therapy, exclusive 
enteral nutrition, inflammatory bowel disease, Crohn’s disease, corticosteroids, pediatric, nutrition, and 
steroids. Articles were excluded with patients > 18 years of age, confounding variables, inclusion of 
other treatment options, or physician discretion bias in selecting a treatment option. Results: 
Ultimately, three articles were included in our review. Two of three studies examined showed a 
statistically significant improvement in remission rates in patients receiving EEN with one study showing 
similar rates. Patients receiving EEN were also noted to have improved intestinal healing, improved 
growth, and decreased need for biologic agents compared to patients receiving CS treatment. 
Conclusion: EEN appears to be an effective and possibly more beneficial treatment option as it is 
associated with fewer adverse reactions, promotes intestinal healing, and has similar remission and 
relapse rates as CS. It cannot be confirmed that EEN will be the preferred induction therapy as the 
treatment choice must be individualized. Further studies must be done to expand knowledge on the 
topic. Cost effectiveness and patient compliance are drawbacks to EEN therapy.  
Introduction 
Crohn’s disease (CD), a form of inflammatory bowel disease, causes transmural inflammatory 
disease affecting all parts of the gastrointestinal tract in children and adults. Patients typically 
experience gastrointestinal symptoms including bloody diarrhea, abdominal tenderness, and 
tenesmus. As well, they suffer from constitutional symptoms of fever and fatigue and extra-
intestinal symptoms including arthritis, aphthous ulcers, and liver disease.1 The etiology of CD is not 
completely understood but is thought to be an immunological response in susceptible individuals, 
the result of a number of genetic and environmental influences.2 Incidence of CD peaks between 
the ages of 15 and 30 years with pediatric patients often experiencing more extensive and severe 
disease.1,3 CD can be particularly devastating in the pediatric population as it can lead to low body 
weight and growth failure based on the degree of inflammation, presence of malnutrition, and 
medical therapy used.3  
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 The two mainstays of induction treatment options for Crohn’s disease are corticosteroids 
(CS) and exclusive enteral nutrition (EEN). CS are either given intravenously (IV) or orally while EEN 
consists of patients receiving their daily nutrition via liquid formulations either orally or through a 
nasogastric or gastrostomy tube. There are a variety of formulas that can be utilized in EEN, but no 
optimal formulation has been identified.4 Corticosteroids are more commonly used in the U.S., but 
they are associated with more adverse effects. These include low bone mineral density, adrenal 
suppression, and growth retardation. EEN has far less adverse effects which consists of 
gastrointestinal irritation causing nausea, vomiting, and diarrhea.5 Despite the improved safety 
profile, EEN has been shown to have poor compliance with a high dropout rate due to the 
unpleasant taste of the formulations or resistance to placement of a nasogastric or gastrostomy 
tube.6 
 Although there are many adverse side effects, CS remains the mainstay for short term 
induction treatment for moderate to severe CD in pediatric patients.7 It is suggested that there can 
be significant benefit to the long-term outcomes of patients who are treated with EEN during their 
induction therapy with significantly fewer side effects compared to the use of CS. The goal of this 
review will be to compare the efficacy of CS to EEN specifically evaluating time to achieve clinical 
remission in pediatric patients with CD receiving these two therapies. 
Methods 
 Articles for review were identified through a search of PubMed in September 2018 using the 
search terms “enteral nutrition therapy, exclusive enteral nutrition, inflammatory bowel disease, 
Crohn’s disease, corticosteroids, pediatric, nutrition, and steroids.” Articles that were excluded 
consisted of case reports or meta-analyses, studies noted to have confounding variables, inclusion 
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of patients >18 years of age, studies that did not compare the two desired variables or had small 
sample size, or were published before 2005. This search resulted in ten articles. Five articles were 
screened and two were excluded due to confounding variables, inclusion of other treatment 
options, or physician discretion bias in selecting a treatment option. Three articles directly 
comparing the use of exclusive enteral nutrition therapy and corticosteroids to induce remission in 
pediatric patients with CD were identified and included in this literature review due to their sample 
sizes, strength of study design, recent completion dates, and inclusion of the desired variables with 
minimal confounding factors. This process is outlined in Figure 1. 
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Figure 1. PRISMA flow diagram demonstrating the process of article selection.  
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Results 
Study #1: Exclusive Enteral Nutrition Therapy in Pediatric Crohn’s Disease Results in Long-term 
Avoidance of Corticosteroids: Results of a Propensity-score Matched Cohort Analysis. Connors et al.8 
Objective: To examine the differences in remission rate (assessed by Pediatric Crohn’s Disease 
Activity Index (PCDAI)) (Appendix A), steroid avoidance, need for immunomodulator or biologic 
pharmacotherapy, linear growth, and need for surgical resection 2, 4, and 6 years post induction 
treatment for CD with CS or EEN.  
Study Design: This retrospective cohort study examined 111 patients aged 3-16 years with newly 
diagnosed CD by clinical, endoscopic, radiologic, and/or histological criteria receiving induction 
therapy in Nova Scotia from 2001-2005 from a prospectively maintained departmental database. 
Children received induction therapy for CD with EEN for 8-16 weeks, provided by mouth or via 
nasogastric tube (NGT) (n=76) or CS therapy with prednisone or budesonide (n=35). PCDAI was 
calculated at diagnosis and reassessed at a 4-12 week follow-up visit to assess remission (defined as 
PCADI <7.5). Results were analyzed using multinomial logistic regression analysis while controlling 
for factors including gender, age, weight, height, PCADI score at diagnosis, disease location, and 
presence of perianal disease. 
Study Results: All patients in the study had a documented PCDAI score <10 at the time of diagnosis. 
After 4-12 weeks of induction therapy, there was a statistically significant higher number of patients 
who achieved clinical remission (PCADI <7.5) in the EEN group (86.6%), compared to the CS group 
(58.1%) (p<0.01) (Table 1).  
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Table 1. Comparison of PCDAI Score and Incidence of Clinical Remission Achieved in CS and EEN 
Groups 
 Corticosteroids EEN p-Value 
PCADI Score at Baseline (median) 30  9.1 30  11.6 0.43 
PCADI Score at follow-up (4-12 weeks) 
(median) 
7.5  10.2 2.5  4.3 <0.01 
Remission by 12 weeks (%) 58.1 86.6 <0.01 
 
The EEN group did show a statistically significant improvement in linear height one year 
following diagnosis compared to the CS group (p<0.01). Patients on EEN also were noted to have 
less frequent use of biologic therapy within 2 years of diagnosis and were less likely to be exposed 
to steroids during the 6-year follow-up period, although this was not statistically significant. 
Immunomodulator use was almost equal between the two groups at 4 weeks after initiating 
induction and did not have a significant impact on achieving remission in either group. Additionally, 
there was no difference in hospitalization rate over the subsequent two years or need for CD-
related surgery between the two groups. Overall, the authors concluded that EEN was an effective 
induction method for pediatric patients with CD that can lead to high rates of remission, 
improvement in linear growth, and avoidance of steroids and other drugs to control disease. 
Study Critique: Although this study was a retrospective cohort study, it was one of the stronger 
study designs found, one of the largest subject sizes, and directly compared the two desired 
variables with minimal contribution from confounding variables. The duration of follow-up for up to 
6 years was also a strength of this study. The biggest weakness of the study was the lack of 
randomized selection, which could introduce bias between the groups. While disease severity and 
location were controlled for, health care providers may have been more likely to recommend EEN 
for patients seeming more compliant or by patient choice.  
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Study #2: Polymeric Diet Alone Versus Corticosteroids in the Treatment of Active Pediatric Crohn’s 
Disease: A Randomized Controlled Open-Label Trial. Borrelli et al.9 
Objective: To compare the efficacy of nutritional therapy alone versus corticosteroids in patients 
newly diagnosed with Crohn’s disease in terms of remission rates and intestinal healing as 
documented by endoscopy and histology. 
Study Design: This was an open-label randomized controlled trial involving 37 patients. The patients 
were required to be 18 years of age or younger, had a recent diagnosis of Crohn’s disease within 
the last 12 weeks, have a moderate-to-severe disease state determined by the PCADI, and the 
ability to start treatment right away. Exclusion criteria are listed in Table 2. The patients were 
randomly placed into a treatment group via a computer-generated randomization schedule to 
receive a 10-week course of their designated treatment. 19 were assigned polymeric diet (intact 
protein formula), and 18 were assigned corticosteroid treatment. The patients could not be 
receiving any other treatment for their Crohn’s disease; however, treatment with proton pump 
inhibitors and H2-receptor antagonists was allowed. 
Table 2. Patient Exclusion Criteria  
Exclusion criteria for Borelli et al. Study 
Fistulizing and/or anorectal CD 
Stenosing CD 
Pre-existing systemic disease 
Hepatic or renal dysfunction 
Lung disease  
Suspected pregnancy 
Contraindication to corticosteroid therapy  
Received corticosteroid therapy within 4 weeks of randomization  
Previous treatment with immunosuppressive agents at any time 
 
Those chosen to receive the oral polymeric diet were also allowed to consume clear liquids. 
A pediatric dietitian calculated the amount of polymeric feed needed to meet 120-130% of the 
patient’s recommended daily requirements. A NGT was utilized if the patient was unable to 
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consume it orally. Those chosen to receive CS followed a dosing regimen with methylprednisolone. 
The dose was determined using the patient’s body weight and was determined to be 1.6 mg/kg/day 
for 4 weeks then a 6-week tapering course until 5-10 mg/day dose was met.  
Assessment of each patient was performed at baseline and at 2, 4, 5, 8, and 10 weeks after 
treatment initiation utilizing the PCDAI. A complete blood count (CBC), erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP) level, albumin, urea, iron, creatinine, electrolytes, and 
pancreatic and liver function tests were obtained at each visit. Additionally, patients were assessed 
for proteinuria and hyperglycemia at each visit. 
Each patient had an ileocolonscopy performed at baseline and after the 10 weeks of 
treatment was finished. Biopsies were taken from the most inflamed areas and read by the same 
pathologist. Endoscopy was also performed, and lesions were graded according to the Crohn’s 
Disease Endoscopic Index of Severity. Each endoscopy was performed by the same operator who 
was unaware of any patient information or the treatment modality.  
Study Results: Children were chosen to participate in the trial and were randomized into treatment 
groups. Five of these children withdrew for various reasons. Using the intention-to-treat analysis, 
79% of the polymeric diet group reached clinical remission with a 95% confidence interval while 
67% of the corticosteroid group reached clinical remission with a 95% confidence interval but was 
not found be statically significant (P=0.4). Using the per-protocol basis, there was no statistical 
significance between the two treatment modalities in terms of clinical remission. The PCDAI scores 
used to determine clinical remission decreased similarly and with statistical significance in both 
groups at the end of the 10-week treatment period. Additionally, there was no statistically 
significant difference in ESR, CRP, or albumin levels at the end of the trial. 
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For both the intention-to-treat and per-protocol analysis, there was improved healing of 
intestinal inflammation in the oral polymeric diet treatment group. For intention to treat, 74% of 
polymeric diet patients showed healing while only 33% of the corticosteroid group did. For per-
protocol analysis, 82% of polymeric diet patients showing healing while only 40% of the 
corticosteroid group did.  
The post-trial endoscopic score was only significantly lower in the group receiving oral 
polymeric diet therapy. Ulcerative lesions in the ileum disappeared in 87% of the polymeric diet 
patients and in only 42% of the corticosteroid patients. Ulcerative lesions in the colon disappeared 
in 75% of polymeric diet patients and in only 31% of corticosteroid patients. There was found to be 
a significant decrease in both histological ileal and colonic scores in only the polymeric diet group. 
Throughout the trial, it was noted that side effects occurred significantly less in the PD 
group than the CS group. Of the PD patients, 23% reported an adverse effect while 67% of the CS 
patients reported one. The most common side effect of the polymeric nutrition was flatulence 
followed by vomiting whereas the most common side effect of corticosteroid therapy was a 
cushingoid appearance.   
Study Critique: Strengths of this study included a randomized controlled study design with few to no 
confounding variables. Using a computer program to assign treatment groups prevented any bias. 
The study focused on the use of the same operator to perform the endoscopies and the same 
pathologist to interpret biopsy results, which prevented any interobserver error. Including patients 
recently diagnosed with CD who have not yet received treatment is beneficial in helping providers 
determine the initial mainstay of treatment. 
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There are several limitations to this study. The small population size does not reflect the 
prevalence of this disease throughout the world. Losing several patients to follow-up worsened this 
problem further. The study only looked at the initial and short-term impact of these treatment 
modalities. The patients were only followed for 10 weeks, which fails to address any long-term 
issues, complications, or disease trends that may arise following this period.  
Study #3: Outcomes of exclusive enteral nutrition in paediatric Crohn’s disease. Lafferty et al. 10 
Objective: This was a two-part study that compared remission rates of Crohn’s disease in pediatric 
patients using EEN and treatment with CS. The first part was a case-matched analysis that 
compared outcomes of patients with Crohn’s disease who used either EEN or CS as their initial 
treatment. The second part was a retrospective cohort study that looked at outcomes of patients 
who received EEN at any point in their treatment. Disease activity was classified using the PCDAI. 
Study Design:  
Case-matched analysis: The EEN treatment consisted of a liquid enteral formula, either polymeric or 
elemental (completely hydrolyzed protein formula), and was given either orally or through NGT as 
the patient’s sole nutrition source for 6-8 weeks. This study allowed for these patients to have 
negligible amounts “non-nutritive treat foods” such as jelly, boiled sweets, and gum, with minimal 
caloric value. The CS therapy consisted of prednisolone 1mg/kg (with a maximum 40 mg dose) once 
daily for 4 weeks followed by a weekly 5 mg taper for the next 7 weeks.  
Patients were eligible for the study if either the EEN or CS was their primary treatment. Each 
EEN patient was then matched with a similar CS patient based on age, gender, disease location, and 
disease activity. Patients were excluded from the study if they had received previous treatment for 
their CD, if EEN was not fully successful within 7 days of starting, or if other CD medications or 
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biologics were started. The patients could be on medications for other conditions, which was 
thoroughly documented in the study.  
Retrospective cohort: Any patient that underwent EEN therapy regardless of disease stage or prior 
treatments was eligible for this study. Patients with ulcerative colitis or unclassified inflammatory 
bowel disease were excluded. Based on the stage of disease when EEN therapy was provided, the 
patients were placed into three different categories. They were classified as “initial” if it was their 
primary treatment, “subsequent” if it was a second-line treatment within 3 months of diagnosis, or 
“relapse” if it was used to treat a patient previously in remission.  
For both studies, the data was obtained from existing hospital databases. PCDAI scores, 
albumin, hematocrit, hemoglobin, platelets, ESR, and CRP were all recorded before and after 
treatment. The study looked at the duration from remission to the next relapse and the number of 
relapses over a 1-year period following treatment.  
Study Results: Case-matched analysis: The study compared 28 patients undergoing EEN treatment 
to 28 patients undergoing CS treatment. Of patients receiving EEN, 86% achieved remission 
compared to the 54% of patients receiving CS (P=0.02). Additionally, EEN patients took an average 
of 3 months to relapse compared to CS patients who took about 2 months to relapse. However, 
there was no statistically significant difference in the number of relapses in the first year among 
treatment groups.  
 Retrospective Cohort analysis: Fifty-nine patients were included in this study. Of this group, 69% 
achieved clinical remission. The highest remission rates were among patients in the “initial” and 
“subsequent” treatment groups. Within 1 year following treatment, 95% of the patients 
experienced a relapse.  
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Study Critique: There were several strengths of this study. This study compared very similar patients 
receiving different treatment modalities. There were straightforward guidelines on the methods of 
treating with EEN therapy or CS therapy as defined per hospital protocol. Following the patients for 
1 year after the treatment was completed allowed for brief insight into the complications and 
progression of the disease. 
Limitations of this study included confusion in combining two different study-types in one 
article. The sample size was small given the number of pediatric patients that suffer from Crohn’s 
disease in Ireland and brings into question how representative this is of CD patients throughout the 
world. A downfall of the inclusion and exclusion criteria was that patients were able to take 
medications for other conditions, which could have influenced the outcomes and acted as 
confounding variables. Since CD is a lifelong illness, a study that follows patient for longer than 1 
year would certainly be more beneficial to look at disease progression following treatment.  
Discussion 
 This review has provided evidence that EEN is as effective as CS when used as an induction 
therapy, if not more effective, in inducing remission in pediatric patients with CD. Two of the three 
studies examined showed a statistically significant improvement in remission rate in patients 
receiving EEN with one study showing similar rates of remission.8–10 In addition to showing success 
as an induction therapy, patients on EEN were noted to have improved intestinal healing, improved 
growth, and decreased use of biologic agents compared to CS without an increase in episodes of 
relapse. While larger, more powerful trials are needed to prove these results, the findings are 
encouraging that EEN can be used as an effective and safer alternative to induce remission in 
children with CD.  
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 Although these results are scientifically promising, the studies examined are not without 
flaws. Overall, the study sizes were small with only one study of greater than 100 patients; 
therefore, it is difficult to say how the results will apply to the population at large. Despite the small 
sample sizes, the study populations were relatively homogeneous with patients of similar ages who 
were newly diagnosed with CD. The long-term follow-up time was inconsistent between studies 
with only one study following patients for six years, although dropout rate was high by this point in 
this study. Therefore, it is difficult to say exactly how EEN will affect long term outcomes in patients 
with CD.  
The study design likely contributed to potential bias introduced in this review. Lafferty et al. 
was the only randomized controlled trial; therefore, bias could have been an influence in the other 
two retrospective cohort studies. Patients were assigned to a treatment group by the treating 
physician. Patients that were more compliant or motivated could have been chosen for the EEN 
group, increasing treatment compliance and, therefore, inducing remission at a higher rate. 
Compliance with EEN therapy could also have been altered depending on if the formula was 
provided by mouth or by NGT. Neither study that allowed EEN administration through NG tube 
discussed the potential adverse effects that could occur, such as aspiration or infection. The studies 
also varied in what additional foods were allowed in addition to enteral formula, which could 
significantly skew results depending on the nutrition content of the foods allowed. The studies were 
all analyzed using different statistical methods, and not all results were statistically significant. 
Lastly, evaluation of side effects of treatment in the studies was subjectively measured. Limitations 
in this population are difficult to overcome; however, studies were screened to attempt to 
maximize reliability. 
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Additional drug therapy allowed also varied between studies. Borrelli et al. allowed patients 
to take proton pump inhibitors or H2 blockers in addition to the prescribed induction treatment, 
which could have altered gut function and impacted remission rate. Lafferty et al. also accepted 
patients into the EEN group who had received previous treatments prior to starting EEN. Lastly 
Borelli et al. used both prednisone and methylprednisolone as CS options for patients in this group. 
Conclusion 
              EEN therapy has proven to be the more beneficial treatment option as it causes fewer 
adverse reactions, promotes better intestinal healing, and has very similar remission and relapse 
rates as compared to CS therapy. However, it is difficult to state that EEN is the preferred induction 
therapy for every patient as many factors are involved in choosing the best treatment plan and 
must be individualized. There are certainly issues to address in future studies that could expand the 
knowledge on the topic and help clinicians make better decisions.  
Each of the studies in this review took place in a different country with none of them being 
in the United States. The patient population is going to vary country to country, and the way 
medicine is practiced could differ as well. It is then important to consider if these results can be 
applied to an international population. Future studies involving a wide variety of countries with 
some taking place in the United States could be more applicable.  
While this review has established EEN as an effective treatment method, it does not identify 
one specific formula type or administration route as being more efficacious. These results could 
ease clinician decision making and benefit patient outcomes. Future studies comparing polymeric 
and elemental formulas as well as oral and NG tube administration should be performed. Future 
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studies could assess other benefits of EEN such as its impact on bone density and relapse rate. Later 
studies could provide further evidence that EEN is a more beneficial treatment option.   
Since Crohn’s is a lifelong irreversible disease, it is important to follow these patients long-
term to truly understand the effects of treatment, remission, and relapse rates. The lack of follow-
up inhibits us from knowing any potential long-term side effects either of the treatment modalities 
may have caused. These studies mostly looked at using EEN as an initial induction treatment, which 
means there is a need to know how relapsing patients respond to EEN compared to CS. Future 
studies with extended patient follow-up could close some of these knowledge gaps.  
Lastly, it is important to consider the cost effectiveness of these two treatment modalities. 
It is important to note that EEN therapy is far more expensive than CS therapy. While EEN may be 
more beneficial, some patients may be unable or unwilling to pay the high costs associated with it. 
EEN treatment for 10 weeks can cost an average of $3,500. Information about insurance coverage is 
unclear and seems specific to the insurance plan. CS treatment for 10 weeks can cost an average of 
$70 to $130 even without insurance.11,12 A thorough patient-provider discussion should address the 
financial burdens of each as well as the pros and cons of each treatment modality to ensure the 
best choice is made. 
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Appendix A. Pediatric Crohn’s Disease Activity Index (PCDAI)13  
 
Paediatric Crohn’s Disease Activity Index 
 
ITEM POINTS 
Abdominal pain 
None 
Mild (brief episodes, not interfering with activities)   
Moderate/severe (frequent or persistent, affecting with activities) 
  
0 
5 
10 
Stools 
0-1 liquid stools, no blood 
2-5 liquid or up to 2 semi-formed with small blood 
Gross bleeding, >6 liquid stools or nocturnal diarrhoea  
  
0 
5 
10 
Patient functioning, general well-being (Recall, 1 week) 
No limitation of activities, well 
Occasional difficulties in maintaining age appropriate activities, below par 
Frequent limitation of activities, very poor 
  
0 
5 
10 
EXAMINATION   
Weight 
Weight gain or voluntary weight loss 
Involuntary weight loss 1-9% 
Weight loss >10%  
  
0 
5 
10 
Height 
< 1 channel decrease (or height velocity > -SD) 
> 1<2 channel decrease (or height velocity < -1SD> -2SD) 
> 2 channel decrease (or height velocity < -2SD) 
  
0 
5 
10 
Abdomen 
No tenderness, no mass 
Tenderness, or mass without tenderness 
Tenderness, involuntary guarding, definite mass 
  
0 
5 
10 
Peri-rectal disease 
None, asymptomatic tags 
1-2 indolent fistula, scant drainage, tenderness of abscess 
Active fistula, drainage, tenderness or abscess 
  
0 
5 
10 
Extra-intestinal manifestations 
Fever > 38.5 x 3 days in week, arthritis, uveitis, erythema nodosum, or pyoderma gangrenosum 
 None 
One 
Two 
   
  
0 
5 
10 
LABORATORY    
Hct (%) 
<10yrs                 11-14 (male)           11-19 (female)           15-19 (male) 
 > 33                        > 35                       > 34                          > 37 
28-33                       30-34                     29-33                        32-36 
 < 28                        < 30                       < 29                          < 32 
  
  
0 
2.5 
5 
ESR (mm/hr) 
    < 20 
     20-50 
     > 50 
  
0 
2.5 
5 
Albumin (g/L) 
     >35 
    31-34 
    <30 
  
0 
5 
10 
 
 
TOTAL =  
Disease activity 
<10 – remission 
10‐27.5 – mild 
30‐37.5 – moderate 
>40 – severe 
